Are Incretin Therapies All Alike? Maximizing Treatment Potential for Type 2 Diabetes Patients in Primary Care

The Woodlands, TX US
May 31, 2014

Despite major recent advances in diabetes care, a large proportion of patients do not achieve glycemic control. There is a clear need for treatments that offer effective glucose control while addressing the comorbid factors associated with diabetes, such as obesity and risk of cardiovascular disease, without the risk of hypoglycemia. This is a case-based lecture focusing on the clinical differences between incretin agents and their place in guidelines.  

Target Audience

This activity is relevant to physicians, physician assistants, nurses, and other healthcare providers.

Learning Objectives

  • Differentiate between incretin-based therapies with respect to important clinical effects beyond glycemic control in patients with type 2 diabetes (T2D)
  • Apply clinical practice guidelines for the management of patients with T2D to appropriately and effectively incorporate incretin-based therapy into treatment plans
  • Develop T2D treatment plans that meet the individual patient’s therapeutic needs and preference

Additional Information

Target Audience: 
Clinical researcher
Scientific researcher
Nurse/Nurse practitioner
Physician assistant
Allied health professional
Competency Area: 
Medical Knowledge
Topic Area: 
Diabetes and Glucose Metabolism
General Endocrinology
Level of Outcomes: 
Level 1 (Participation)
Activity summary
Available credit: 
  • 1.00 AMA PRA Category 1 Credits
Course opens: 
Course expires: 
Event starts: 
05/31/2014 - 9:00am
Event ends: 
05/31/2014 - 10:00am
The Woodlands Waterway Marriott
1601 Lake Robbins Dr
The Woodlands, TX 77380
United States

Faculty Disclosures




Carol H. Wysham, MD

Clinical Associate Professor of Medicine

University of Washington

Section Head,

Rockwood Center for Diabetes and Endocrinology

Rockwood Clinic

Spokane, Washington






Speakers Bureau



Astra Zeneca, Jansen, Sanofi



Astra Zeneca, Jansen, Novo Nordisk, Sanofi

Available Credit

  • 1.00 AMA PRA Category 1 Credits